Teleflex Enters a Definitive Agreement to Acquire BIOTRONIK’s Vascular Intervention Business for ~$797.7M (€760M)
Shots:
- Teleflex to acquire BIOTRONIK's vascular intervention business for ~$797.7M (€760M) in cash, subject to adjustments. Closing expecting in Q3’25
- Acquisition will expand Teleflex’s interventional portfolio with coronary products like Pantera Lux Catheter, PK Papyrus Covered Stent & Orsiro Stent, plus peripheral product like Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent, complementing to its PCI platform
- Acquisition also allows Teleflex to advance development of BIOTRONIK’s Freesolve, which was assessed in BIOMAG-I trial showing superior post 12mos. resorbability & target lesion failure rate with no scaffold thrombosis. Enrolment is ongoing in European BIOMAG-II trial
Ref: Globenewswire | Image: BIOTRONIK
Related News:- Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
